Ascletis Pharma Initiates U.S. Clinical Study on Obesity Treatment

An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.

Ascletis Pharma Inc. has announced the dosing of the first participants in a U.S. clinical study combining their adipose-targeted small molecule THR β agonist, ASC47, with semaglutide for obesity treatment. This study aims to evaluate the safety and preliminary efficacy of ASC47, which has shown promising results in preclinical models by significantly enhancing weight loss with muscle preservation compared to semaglutide alone. The outcome of this study could potentially impact the company’s position in the obesity treatment market, with topline data expected by the fourth quarter of 2025.

The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company specializes in creating treatments for metabolic diseases, including obesity, and is known for its adipose-targeted, muscle-preserving weight loss drug candidates.

Average Trading Volume: 7,221,678

Technical Sentiment Signal: Buy

Current Market Cap: HK$5.47B

For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.